WO2023191515A1 - Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un dérivé d'indirubine et un activateur métabolique - Google Patents

Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un dérivé d'indirubine et un activateur métabolique Download PDF

Info

Publication number
WO2023191515A1
WO2023191515A1 PCT/KR2023/004211 KR2023004211W WO2023191515A1 WO 2023191515 A1 WO2023191515 A1 WO 2023191515A1 KR 2023004211 W KR2023004211 W KR 2023004211W WO 2023191515 A1 WO2023191515 A1 WO 2023191515A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
formula
activator
alkyl
group
Prior art date
Application number
PCT/KR2023/004211
Other languages
English (en)
Korean (ko)
Inventor
최강열
류영찬
김건욱
Original Assignee
연세대학교 산학협력단
주식회사 씨케이리제온
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020230015930A external-priority patent/KR20230141447A/ko
Application filed by 연세대학교 산학협력단, 주식회사 씨케이리제온 filed Critical 연세대학교 산학협력단
Publication of WO2023191515A1 publication Critical patent/WO2023191515A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Definitions

  • the present invention relates to a composition for preventing hair loss or promoting hair growth containing an indirubin derivative and a metabolic activator.
  • the anagen phase is the period when hair grows
  • the catagen phase is the period when the metabolic process slows down while maintaining the shape of the hair after the growth period ends. During this period, hair growth slows down.
  • the catagen stage is a period in which hair follicle cell division stops and rapidly shrinks.
  • the final telogen phase is a period in which hair follicle activity completely stops and prepares for hair loss. The telogen hair is pushed out by new growth-phase hair growing at the base and falls out on its own, and is easily removed by physical actions such as combing or washing the hair. This cycle repeats over 3 to 6 years.
  • Hair loss refers to a condition in which there is no hair in areas where hair should normally exist.
  • the papilla present at the hair root becomes smaller, and as the papilla becomes smaller, the thickness of the hair becomes thinner and at the same time, the hair cycle becomes shorter and new growth occurs.
  • the hair that comes out becomes thinner. In other words, as hair loss progresses, the hair turns into fluff and the hair cycle becomes shorter, so the hair grows a little and falls out immediately.
  • DHT dihydrotestosterone
  • Testosterone a type of male hormone, is activated into DHT by the 5 ⁇ -reductase enzyme, and this DHT is known to induce hair loss.
  • DHT causes hair follicles to atrophy, causing vellus hair to become thin and limp.
  • hair root-destroying substances are secreted, causing the hair to enter the catagen stage at an early stage, resulting in hair loss.
  • Hair loss treatments developed to date include finasteride (brand name: Propecia®), dutasteride (brand name: Avodart®), and minoxidil (brand names: Minoxil® or Rogaine®).
  • Minoxidil can cause side effects such as edema, arrhythmia, and hair growth in unwanted areas when applied long-term. It is known that the effect of minoxidil is greatest between 6 months and 1 year after use, and the effect gradually decreases thereafter.
  • Finasteride and dutasteride inhibit DHT production by blocking the action of the 5 ⁇ -reductase enzyme, but have side effects such as decreased libido, erectile dysfunction, and loss of driving and performance abilities.
  • hair transplant surgery has recently been attempted for patients with severe hair loss, but the high cost and side effects after the procedure have been pointed out as limitations.
  • the present inventors conducted repeated research to develop a drug with fewer side effects and excellent hair loss improvement effect, and as a result discovered that indirubin derivatives and metabolic activators have excellent hair loss improvement effect, thereby completing the present invention. .
  • Patent Document 1 Republic of Korea Patent Publication No. 10-2022-0032974
  • the present invention was devised to solve the above problems, and the object of the present invention is to provide a pharmaceutical composition for preventing or treating hair loss that contains an indirubin derivative and a metabolic activator as active ingredients and has no side effects on the human body.
  • the present invention provides a cosmetic composition and food composition for preventing or improving hair loss containing the indirubin derivative and the metabolic activator as active ingredients.
  • Another object of the present invention is to provide a method for preventing, improving, or treating hair loss that has an excellent hair loss prevention or treatment effect and includes an indirubin derivative and a metabolic activator as active ingredients.
  • the present invention is intended to provide a new use of a composition containing an indirubin derivative and a metabolic activator for the prevention or treatment of hair loss.
  • the present invention includes an indirubin derivative represented by the following formula (1) and a metabolic activator as active ingredients, and the metabolic activator is a PKM2 (pyruvate kinase M2) activator or MPC (Mitochondrial pyruvate carrier)
  • a pharmaceutical composition for preventing or treating hair loss which is an inhibitor.
  • R 1 to R 5 are each independently hydrogen, halogen, hydroxy, nitro, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted or unsubstituted C 6 -C 10 aryl, and C 7-30 aryl. It is any one selected from the group consisting of alkyl.
  • R 1 to R 3 are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy
  • R 4 is hydrogen or C 1 - C 6 alkyl
  • R 5 may be any one selected from the group consisting of hydrogen, C 1 -C 6 alkyl, substituted or unsubstituted C 6 -C 10 aryl, and C 7-30 arylalkyl.
  • R 3 and R 4 may be hydrogen.
  • R 1 and R 2 may each independently be selected from the group consisting of hydrogen, halogen, and -O-CH 3 .
  • R 5 may be any one selected from the group consisting of hydrogen, C 1 -C 3 alkyl, substituted or unsubstituted C 6 -C 10 aryl, and C 7-10 arylalkyl.
  • Formula 1 may be any one selected from the following Formulas 1-1 to 1-4.
  • the PKM2 (pyruvate kinase M2) activator is 6-[(3-aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5H-thieno[2',3':4,5 ]pyrrolo[2,3-d]pyridazin-5-one(TEPP-46, ML265), 3-(4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-ylsulfonyl)-1, It may be any one selected from the group consisting of 4-diazepan-1-ylsulfonyl)aniline (DASA-58) and serine, and the MPC (Mitochondrial pyruvate carrier) inhibitor is (E)-2-Cyano-3- It may be (1-phenyl-1H-indol-3-yl)acrylic acid (UK5099).
  • the indirubin derivative and the metabolic activator may be included in a molar ratio of 1:0.1 to 10.
  • the present invention includes an indirubin derivative represented by the following formula (1) and a metabolic activator as active ingredients, and the metabolic activator is a PKM2 (pyruvate kinase M2) activator or MPC (Mitochondrial pyruvate carrier) )
  • the metabolic activator is a PKM2 (pyruvate kinase M2) activator or MPC (Mitochondrial pyruvate carrier)
  • PKM2 pyruvate kinase M2
  • MPC Mitochondrial pyruvate carrier
  • R 1 to R 5 are each independently hydrogen, halogen, hydroxy, nitro, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted or unsubstituted C 6 -C 10 aryl, and C 7-30 aryl. It is any one selected from the group consisting of alkyl.
  • the composition may promote the proliferation of dermal papilla cells or hair follicle cells in vitro.
  • the cosmetic composition includes hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair nutrition cream, hair moisture cream, hair massage cream, hair wax, and hair aerosol.
  • hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair oil, hair dryer, hair preservation treatment, hair dye, hair waving agent, hair bleach, hair gel, hair glaze, hair dresser, hair lacquer, hair moisturizer It may be any one hair formulation selected from the group consisting of hair mousse and hair spray.
  • the present invention includes an indirubin derivative represented by the following formula (1) and a metabolic activator as active ingredients, and the metabolic activator is a PKM2 (pyruvate kinase M2) activator or MPC (Mitochondrial pyruvate)
  • a food composition for preventing or improving hair loss which is characterized as being a carrier inhibitor.
  • R 1 to R 5 are each independently hydrogen, halogen, hydroxy, nitro, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted or unsubstituted C 6 -C 10 aryl, and C 7-30 aryl. It is any one selected from the group consisting of alkyl.
  • the present invention provides a method for preventing or treating hair loss, which includes administering an indirubin derivative represented by the following formula (1) and a metabolic activator to a hair loss patient.
  • R 1 to R 5 are each independently hydrogen, halogen, hydroxy, nitro, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted or unsubstituted C 6 -C 10 aryl, and C 7-30 aryl. It is any one selected from the group consisting of alkyl.
  • the present invention provides a new use of an indirubin derivative and a metabolic activator represented by the following formula (1) as a drug for preventing or treating hair loss.
  • the metabolic activator is characterized as being a PKM2 (pyruvate kinase M2) activator or MPC (Mitochondrial pyruvate carrier) inhibitor.
  • R 1 to R 5 are each independently hydrogen, halogen, hydroxy, nitro, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted or unsubstituted C 6 -C 10 aryl, and C 7-30 aryl. It is any one selected from the group consisting of alkyl.
  • the present invention provides a method for producing a pharmaceutical agent having a hair loss prevention or treatment effect, characterized by using an indirubin derivative and a metabolic activator represented by the following formula (1): .
  • R 1 to R 5 are each independently hydrogen, halogen, hydroxy, nitro, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted or unsubstituted C 6 -C 10 aryl, and C 7-30 aryl. It is any one selected from the group consisting of alkyl.
  • composition according to the present invention can be usefully used as a pharmaceutical composition or cosmetic composition capable of preventing hair loss or promoting hair growth, and can be used in functional cosmetics for preventing hair loss or promoting hair growth, including hair growth promoting agents.
  • the mixed composition of an indirubin derivative and a metabolic activator according to the present invention has the advantage of being a safe material that is non-toxic to cells and does not cause inflammation and does not cause side effects to the human body.
  • the present invention is a composition that mixes an indirubin derivative and a metabolic activator at a certain ratio, and has the advantage of showing a stronger effect on hair growth, wool growth, and hair loss prevention than a single composition.
  • Figure 1 is a micrograph taken after culturing Vibrissa hair follicles treated with indirubin derivatives or metabolic activators (TEPP-46, DASA-58, Serine, UK-5099, Dichloroacetate) alone for 6 days
  • Figure 2 is This is a photomicrograph taken after culturing Vibrissa hair follicles treated with a mixture of indirubin derivatives and metabolic activators (TEPP-46, DASA-58, Serine, UK-5099, Dichloroacetate) for 6 days.
  • Figure 3 shows the length change of each Vibrissa hair follicle treated alone or in combination with an indirubin derivative and a metabolic activator (TEPP-46, DASA-58, Serine, UK-5099, Dichloroacetate) and cultured for 6 days. This is the graph shown (* P ⁇ 0.05, ** P ⁇ 0.005, *** P ⁇ 0.0005, NS: not significant vs. VEH or single treat).
  • a metabolic activator TEPP-46, DASA-58, Serine, UK-5099, Dichloroacetate
  • Figure 4 is a micrograph (top) of Vibrissa hair follicles taken in the group administered with various concentrations of serine alone and a graph (bottom) showing the length change (* P ⁇ 0.05, ** P ⁇ 0.005, *** P ⁇ 0.0005, NS: not significant vs. VEH).
  • Figure 5 shows the cell viability of human dermal papilla cells treated with indirubin derivatives and metabolic activators (TEPP-46, DASA-58, Serine, UK-5099, Dichloroacetate) alone or in combination. This is the graph shown (* P ⁇ 0.05, ** P ⁇ 0.005, *** P ⁇ 0.0005 vs VEH).
  • Figure 6 is a photograph of each group treated with indirubin derivative and metabolic activator (TEPP-46) alone or in combination
  • Figure 7 is a photograph of each group treated with indirubin derivative and metabolic activator (TEPP-46) alone or in combination. This is a graph showing the hair growth values measured from each treated group (* P ⁇ 0.05, ** P ⁇ 0.005, *** P ⁇ 0.0005, NS: not significant vs VEH or single treat).
  • One aspect of the present invention relates to a pharmaceutical composition, cosmetic composition, and food composition for preventing or treating hair loss containing an indirubin derivative represented by the following formula (1) and a metabolic activator as active ingredients.
  • the metabolic activator may be a PKM2 (pyruvate kinase M2) activator or an MPC (Mitochondrial pyruvate carrier) inhibitor.
  • Another aspect of the present invention relates to a method of treating hair loss comprising administering an effective amount of an indirubin derivative represented by Formula 1 and a metabolic activator to a hair loss patient.
  • Another aspect of the present invention relates to a method of treating hair loss comprising administering a therapeutically effective amount of an indirubin derivative represented by Formula 1 and a metabolic activator to a subject.
  • Another aspect of the present invention provides a new use of the indirubin derivative and metabolic activator represented by the following formula (1) as a drug for preventing or treating hair loss.
  • another aspect of the present invention provides a method for producing a pharmaceutical agent having a hair loss prevention or treatment effect, characterized by using an indirubin derivative represented by the following formula (1) and a metabolic activator.
  • the indirubin derivative and metabolic activator represented by Formula 1 are active ingredients that enable the above method and use to be achieved, and may be in the form of a mixture or mixed composition or composition mixed in a certain ratio.
  • the present invention is a composition that mixes an indirubin derivative and a metabolic activator in a certain ratio, and has been confirmed to have excellent effects on preventing hair loss and promoting hair growth, making it possible to prevent hair loss and promote hair growth, and thus can be used in pharmaceuticals, foods, cosmetics, etc. It can be applied to various fields.
  • R 1 to R 5 are each independently hydrogen, halogen, hydroxy, nitro, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted or unsubstituted C 6 -C 10 aryl, and C 7-30 aryl. It is any one selected from the group consisting of alkyl.
  • 'halogen' in the present invention refers to bromo, chloro, fluoro, or iodo, and can be used interchangeably with 'halo' and 'halogen'.
  • alkyl' in the present invention refers to a hydrocarbon having primary, secondary, tertiary, and/or quaternary carbon atoms, and includes saturated aliphatic groups that may be straight-chain, branched, or cyclic, or a combination thereof. do.
  • an alkyl group may have 1 to 20 carbon atoms (i.e., C 1 -C 20 alkyl), 1 to 10 carbon atoms (i.e., C 1 -C 10 alkyl), or 1 to 6 carbon atoms (i.e., C 1 -C 6 alkyl).
  • alkyls examples include methyl (Me, -CH 3 ), ethyl (Et, -C 2 H 5 ), 1-propyl (n-Pr, -CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, -CH(CH 3 ) 2 ), 1-butyl (n-Bu, - CH 2 CH 2 CH 2 CH 3 ), 2-methyl-1-propyl (i-Bu,-CH 2 CH(CH 3 ) 2 ) , 2-butyl (s-Bu, -CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (t-Bu, -C(CH 3 ) 3 ), 1-pentyl (n-pentyl, -CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3 )CH 2 CH 2 CH 3 ), 3-pentyl (-CH(CH 2 CH 3 ) 2 ), 2-methyl- 2-Butyl(-CH(CH 3 ) 2 CH 2 CH
  • 'alkoxy' in the present invention refers to a functional group with -OR in which an alkyl group is attached to the parent compound through an oxygen atom.
  • Examples of C 1 -C 6 alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, and hexoxy.
  • the term 'aryl' refers to an optionally substituted benzene ring, or a ring system that can be formed by fusing one or more optional substituents, and the number of carbon atoms is not particularly limited, but is 6 to 6. Substituted or unsubstituted allyl, which is 30, is preferred.
  • 'aryl' groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, indanyl, anthracyl or phenanthryl, and substituted derivatives thereof.
  • the substituents include C l - 3 alkyl, C 2 - 3 alkenyl, substituted C 2 - 3 alkynyl, heteroaryl, heterocyclic, aryl, alkoxy, aryloxy, aralkoxy, optionally having 1 to 3 fluorine substituents.
  • This ring or ring system may optionally be fused to an aryl ring (eg, a benzene ring), a carbocyclic ring, or a heterocyclic ring, optionally bearing one or more substituents.
  • the substituent may be C 1-3 alkyl
  • aryl substituted with C 1-3 alkyl refers to an aryl group in which one hydrogen is substituted with an alkyl group.
  • the aryl group substituted with C 1-3 alkyl is also called alkylaryl and may be C 7 to C 30 alkylaryl.
  • C 7-30 alkylaryl may be methylphenyl, ethylphenyl, n-propylphenyl, iso-propylphenyl, n-butylphenyl, iso-butylphenyl, tert-butylphenyl, or cyclohexylphenyl, and is preferably C It may be 7 to C 10 alkylaryl.
  • the arylalkyl group is arylalkyl having 7 to 30 carbon atoms, which may mean a substituent in which one or more hydrogens of alkyl are replaced by aryl. Specifically, it may be C 7-30 arylalkyl, preferably benzyl, phenylpropyl, or phenylhexyl, and more preferably, the C 7-10 arylalkyl may be benzyl or phenylpropyl.
  • 'hydroxy' in the present invention refers to the -OH radical.
  • R 1 to R 3 may each independently be selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy, and R 4 is hydrogen or C It may be 1 -C 6 alkyl, but more preferably, in Formula 1, R 1 and R 2 may each independently be any one selected from the group consisting of hydrogen, halogen, and -O-CH 3 , and the formula In 1, R 3 and R 4 may be hydrogen.
  • R 5 may be any one selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and C 6 -C 10 aryl, but more preferably R 5 is hydrogen, C 1 -C 3 alkyl. , substituted or unsubstituted C 6 -C 10 aryl, and C 7-10 arylalkyl.
  • Indirubin represented by Formula 1 is 5-methoxyl indirubin-3'-oxime, indirubin-3'-oxime, 6-bromoindirubin-3'-oxime, 5,6-dichloro indirubin, 5 , 6-dichloro indirubin-3'-oxime, 5,6-dichloro indirubin-3'-methoxime, 5,6-dichloro indirubin-3'-propyl oxime, 6-chloro-5-nitro indirubin, 6-chloro-5-nitroindirubin-3'-oxime, 6-chloroindirubin-3'-methoxime, 5-chloroindirubin-3'-methoxime, 5-bromoindirubin-3'-oxime , 5-bromoindirubin-3'-oxime , 5-bromoindirubin-3'-methoxime, 5-bromoindirubin-3'-ethyloxime, 5,6-dichloroindirubin-3'-oximepropyloxime and 6-
  • Formula 1 may be any one selected from the following Formulas 1-1 to 1-4, but is not limited thereto, and can significantly prevent and treat hair loss and hair growth through combined use with a metabolic activator. Alternatively, it may show an improvement effect, but most preferably, an indirubin derivative represented by Formula 1-1 prevents hair loss when administered in combination with a metabolic activator, not only promotes hair growth or hair growth, but also promotes the proliferation of skin cells. By increasing and inducing, a significant effect beyond the synergistic effect can be achieved compared to single administration.
  • the metabolic activator may be a PKM2 (pyruvate kinase M2) activator or an MPC (Mitochondrial pyruvate carrier) inhibitor, and the PKM2 (pyruvate kinase M2) activator refers to any substance that can promote the expression or activity of PKM2.
  • PKM2 pyruvate kinase M2
  • MPC Mitochondrial pyruvate carrier
  • 6-[(3-aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5H-thieno[2',3':4,5] pyrrolo[2,3-d]pyridazin-5-one(TEPP-46, ML265), 3-(4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-ylsulfonyl)-1,4 -diazepan-1-ylsulfonyl)aniline (DASA-58) may be any one selected from the group consisting of serine, and more preferably 6-[(3-aminophenyl)methyl]-4,6-dihydro It may be -4-methyl-2-(methylsulfinyl)-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one (TEPP-46, ML
  • MPC mitochondrial pyruvate carrier
  • E 2-Cyano- It may be 3-(1-phenyl-1H-indol-3-yl)acrylic acid (UK5099).
  • the term 'hair loss' refers to a state in which there is no hair in areas where hair should normally exist, regardless of the cause, for example, male pattern baldness, female pattern baldness, alopecia areata, telogen effluvium, stress-related. It may be hair loss or hair loss caused by chemotherapy drugs.
  • the composition of the present invention promotes proliferation of dermal papilla cells and growth of hair length, and therefore may be particularly effective in the treatment of male pattern baldness.
  • the indirubin derivative is represented by Formulas 1-1 to 1-4, which shows little toxicity to cells even when treated with cells for a long period of time, and has a significant increase in effect when treated with a metabolic activator. It may be any one or more selected from the group consisting of, and most preferably, it may be an indirubin derivative represented by Formula 1-2. This is because through in vitro experiments, treatment with an indirubin derivative of Chemical Formula 1-2 and a metabolic activator was observed to increase the length of vibrissa by more than 75 to 95% compared to the conventional hair loss treatment agent (minoxidil). Because it has been done.
  • the conventional hair loss treatment agent minoxidil
  • the composition containing an indirubin derivative and a metabolic activator according to the present invention can be used as a pharmaceutical composition and cosmetic composition that prevents hair loss and promotes hair growth by preventing hair follicles from entering the telogen phase and maintaining the growth phase. You can.
  • composition according to the present invention did not show inflammation or other pathological findings and was confirmed to be stable in cytotoxicity tests, and based on this, it can be used as an improvement or treatment for hair loss.
  • the indirubin derivative represented by Formula 1 according to the present invention can be used not only as a free substance, but also as a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable polymorph, or pharmaceutically acceptable prodrug. can be provided.
  • the salt of the indirubin derivative is not particularly limited as long as it is in a form that can be incorporated into medicines or cosmetics. It contains inorganic salts or organic salts and may be acidic salts or alkaline salts.
  • alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as calcium salts, magnesium salts, and barium salts; Basic amino acid salts such as arginine and lysine; Ammonium salts such as ammonium salt and tricyclohexylammonium salt; It may be various alkanol amine salts such as monoethanolamine salt, diethanolamine salt, triethanolamine salt, monoisopropanolamine salt, diisopropanolamine salt, and triisopropanolamine salt.
  • the salt is an alkali metal salt, and more preferably, it may be a tetrasodium salt.
  • the mixing ratio of the indirubin derivative and the metabolic activator is not particularly limited, but may be included at a molar ratio of 1:0.1 to 10, preferably 1:0.1 to 5, and more preferably 1:0.1 to 5. It may be a molar ratio of 0.1 to 3. If it is outside the above range, it is undesirable because the hair loss prevention and hair promotion effects are reduced.
  • the term 'comprising an active ingredient' in the present invention means containing an active ingredient in an amount sufficient to prevent hair loss or promote hair growth in the present invention.
  • the term 'prevention' refers to any action that inhibits or delays hair loss or hair damage by administering the composition according to the present invention
  • 'treatment' refers to improvement of hair loss symptoms by administering the pharmaceutical composition. It means any action that becomes or changes beneficially.
  • the term 'improvement' in the present invention means any act of reducing at least the degree of symptoms, for example, parameters related to the hair loss or hair damage condition treated by administration of the composition containing the indirubin derivative and the metabolic activator of the present invention. means.
  • the pharmaceutical composition of the present invention can be administered parenterally or orally according to the desired method, and preferably may be parenteral administration or topical administration through application.
  • the dosage range varies depending on the patient's weight, age, gender, health condition, diet, administration time, administration method, excretion rate, and severity of the disease.
  • the therapeutically effective amount of the composition may vary depending on the administration method, target area, and patient's condition, and when used in the human body, the dosage should be determined as an appropriate amount considering safety and efficiency.
  • subject refers to an object for which the disease is to be prevented or treated, and preferably includes humans and animals.
  • the upper limit of the dosage is not particularly limited, but the preferred dosage of the composition of the present invention is 0.01 to 1000 mL/kg per day. Preferably, it can be administered at 0.1 to 100 ml/kg, and more preferably at 1 to 10 ml/kg. Administration may be administered once a day, or may be administered several times. The above dosage does not limit the scope of the present invention in any way.
  • the pharmaceutical composition of the present invention can be formulated into oral dosage forms such as powders, granules, tablets, soft or hard capsules, suspensions, emulsions, syrups, and aerosols, skin external preparations such as ointments and creams, suppositories, injections, and the like, respectively, according to conventional methods. It can be formulated and used in any form suitable for pharmaceutical preparations, including sterile injectable solutions.
  • excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and diluents commonly used for the formulation.
  • excipients that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate.
  • cellulose methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate, and mineral oil, but are not limited thereto. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc can also be used.
  • Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
  • Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.
  • witepsol macrogol, tween 61, cacao, laurel, glycerogelatin, etc. can be used.
  • composition according to the present invention may have a dosage form that can be administered by a method such as directly applying or spraying to the skin or wound, for example, a cream, lotion, ointment, aerosol, gel, or pack.
  • a method such as directly applying or spraying to the skin or wound, for example, a cream, lotion, ointment, aerosol, gel, or pack.
  • Methods for mixing ingredients or formulations suitable for each dosage form are well known in the art. When preparing these preparations, those skilled in the art can appropriately select and use various mixing ingredients used in preparing conventional external preparations.
  • such ingredients include white petrolatum, yellow petrolatum, lanolin, bleached beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, gelling hydrocarbons, polyethylene glycol, and liquid paraffin. , squalane, etc., oleic acid, isopropyl myrstate, glycerin triisooctanoate, crotamiton, diethyl sebacate, diisopropyl adipate, hexyl laurate, fatty acids, fatty acid esters, fatty alcohols, vegetable oils.
  • solvents and solubilizers such as tocopherol derivatives, antioxidants such as L-ascorbic acid, dibutylhydroxytoluene, butylhydroxyanisole, preservatives such as parahydroxybenzoic acid ester, glycerin, propylene glycol, and sodium hyaluronate.
  • Moisturizers such as polyoxyethylene derivatives, glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, surfactants such as lecithin, carboxyvinyl polymer, xanthan gum, carboxymethyl cellulose, carboxymethyl cellulose sodium salt, There are thickeners such as hydroxypropylcellulose and hydroxypropylmethylcellulose.
  • the present invention relates to a cosmetic composition for alleviating, suppressing or improving hair loss containing an indirubin derivative represented by Formula 1 and a metabolic activator as active ingredients.
  • the specific description of the cosmetic composition is the same as the description of the pharmaceutical composition for preventing or treating hair loss containing the indirubin derivative represented by Chemical Formula 1 and the metabolic activator as active ingredients, so please refer to that section for detailed information. .
  • ingredients included in the cosmetic composition of the present invention include ingredients commonly used in cosmetic compositions in addition to the indirubin derivative and metabolic activator as active ingredients, such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances. It may include common auxiliaries and carriers such as:
  • the cosmetic composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, solution, suspension, emulsion, paste, gel, shampoo, rinse, conditioner, lotion, lotion, cream, serum. , essence, gel, pack, cleanser, soap, spray, powder, oil, powder foundation, emulsion foundation, and wax foundation, but is not limited thereto, and specifically hair tonic, hair conditioner, and hair essence. , hair lotion, hair nutrition lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair nutrition cream, hair moisture cream, hair massage cream, hair wax, hair aerosol, hair pack, hair nutrition pack, hair soap, hair cleansing foam.
  • the present invention relates to a food composition for preventing or improving hair loss containing an indirubin derivative represented by Formula 1 and a metabolic activator as active ingredients.
  • the specific description of the food composition is the same as the description of the pharmaceutical composition for preventing or treating hair loss containing the indirubin derivative represented by Chemical Formula 1 and the metabolic activator as active ingredients, so please refer to that section for detailed information. .
  • the food composition according to the present invention can be formulated in the same way as the pharmaceutical composition and used as a functional food or added to various foods.
  • Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, gum, ice cream, vitamin complexes, and health supplements. etc.
  • the food composition of the present invention may contain not only the above active ingredients but also ingredients commonly added during food production, including, for example, proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents.
  • examples of the above-mentioned carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, oligosaccharides, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • flavoring agents natural flavoring agents (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
  • thaumatin, stevia extract e.g., rebaudioside A, glycyrrhizin, etc.
  • synthetic flavoring agents sacharin, aspartame, etc.
  • the food composition of the present invention is manufactured as a drink or beverage
  • citric acid, high fructose corn syrup, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be additionally included in addition to the boratin of the present invention.
  • the present invention provides a health functional food containing a food composition for preventing or improving hair loss containing an active ingredient.
  • Health functional foods are foods manufactured by adding the active ingredients of indirubin derivatives and metabolic activators represented by Chemical Formula 1 to food ingredients such as beverages, teas, spices, gum, and confectionery, or by encapsulating, powdering, or suspending them. , which means that ingesting it will bring about certain health effects, but unlike regular drugs, it has the advantage of not having any side effects that may occur when taking the drug for a long time since it is made from food.
  • the health functional food of the present invention obtained in this way is very useful because it can be consumed on a daily basis.
  • the amount of active ingredients added in such health functional foods cannot be uniformly specified as it depends on the type of health functional food being targeted. However, it can be added within a range that does not damage the original taste of the food, and is usually 0.01% for the target food. to 50% by weight, preferably 0.1 to 20% by weight.
  • it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight.
  • the health functional food of the present invention may be in the form of a pill, tablet, capsule, or beverage.
  • the present invention provides a composition for promoting the growth of dermal papilla cells or hair follicle cells isolated from mammalian skin, comprising an indirubin derivative represented by the following formula (1) and a metabolic activator as active ingredients.
  • composition for preventing or treating hair loss containing the indirubin derivative represented by Formula 1 and a metabolic activator as active ingredients, so refer to that section for detailed information.
  • the composition of the present invention can be used as a composition that can promote the proliferation of dermal papilla cells or hair follicle cells in vitro, and can especially be used as a medium composition that can culture the dermal papilla cells and hair follicle cells in vitro.
  • the mammal may be any one selected from the group consisting of humans, cattle, goats, and sheep.
  • the present inventors provide a composition that can efficiently and rapidly mass-produce dermal papilla cells or hair follicle cells in vitro in relation to hair loss or hair growth promotion, and the composition only efficiently causes the growth of dermal papilla cells or hair follicle cells.
  • the composition only efficiently causes the growth of dermal papilla cells or hair follicle cells.
  • large amounts of non-toxic dermal papilla cells and hair follicle cells could be produced at high yield.
  • 5,6-dichloroindirubin-3'-propyloxime and 6-chloroindirubin-3'-benzyloxime are 5,6-dichloroindirubin-3'-methoxime or 5-methoxyl indirubin-3'.
  • -It was synthesized in the same way as oxime, and was dissolved in dimethyl sulfide (DMSO) and applied to the experiment.
  • the metabolic activator used in the present invention is 6-[(3-aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5H-thieno[2',3':4,5]pyrrolo[ 2,3-d]pyridazin-5-one(TEPP-46, ML265), 3-(4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-ylsulfonyl)-1,4-diazepan -1-ylsulfonyl)aniline (DASA-58) and (E)-2-Cyano-3-(1-phenyl-1H-indol-3-yl)acrylic acid (UK5099) and serine were obtained from Sigma Aldrich (St. Louis, USA) and used.
  • Examples 1 to 4 are a mixture of an indirubin derivative represented by Formula 1-2 and a metabolic activator
  • Comparative Examples 1 to 9 are a group administered only an indirubin derivative represented by Formula 1-2 or a metabolic activator.
  • Comparative Examples 10 and 11 contain dichloroacetate, a PDK activator, not a PKM2 activator, alone or mixed with an indirubin derivative among metabolic activators.
  • mice Male mice aged 6 to 8 weeks were sacrificed, and tissues around the mouth were isolated. The separated tissue was placed in 70% ethanol and then washed with PBS (phosphate) containing 1% penicillin (100IU/ml)/streptomycin (100 ⁇ g/ml) (P/S, GIBCO, Grand Island, NY, USA). -buffered saline)pH 7.4, SIGMA, St. Louis, MO, USA) to prepare an emulsion. Using a microscope, vibrissa follicles in the anagen state were separated one by one.
  • PBS phosphate
  • P/S GIBCO
  • SIGMA St. Louis, MO, USA
  • the isolated vibrissa follicles were dispensed into each well of a 24-well plate and then treated with medium containing the examples or comparative examples (DMEM serum free 1% P/S + 12.5 ⁇ g/ml gentamycin).
  • the plate was cultured at 37°C and 5% CO 2 and observed through a microscope after 6 days. The medium was changed once every two days.
  • the hair follicle morphology was photographed under a microscope (SMZ745T, Nikon), and the hair follicle length was measured using image J.
  • the average value of hair follicle length change was calculated and compared with the average length of the negative control group or single treatment group to measure the degree of growth.
  • the results obtained from the experiment were recorded as the mean and its standard error of the mean (SEM), and significance was determined using the Student's T-test analysis method.
  • Figure 1 is a micrograph taken after culturing Vibrissa hair follicles treated with indirubin derivatives or metabolic activators (TEPP-46, DASA-58, Serine, UK-5099, Dichloroacetate) alone for 6 days
  • Figure 2 is This is a photomicrograph taken after culturing Vibrissa hair follicles treated with a mixture of indirubin derivatives and metabolic activators (TEPP-46, DASA-58, Serine, UK-5099, Dichloroacetate) for 6 days.
  • Figure 3 shows the length change of each Vibrissa hair follicle treated alone or in combination with an indirubin derivative and a metabolic activator (TEPP-46, DASA-58, Serine, UK-5099, Dichloroacetate) and cultured for 6 days. This is the graph shown (* P ⁇ 0.05, ** P ⁇ 0.005, *** P ⁇ 0.0005, NS: not significant vs. VEH or single treat).
  • a metabolic activator TEPP-46, DASA-58, Serine, UK-5099, Dichloroacetate
  • Figure 4 is a micrograph (top) of Vibrissa hair follicles taken in the group administered with various concentrations of serine alone and a graph (bottom) showing the length change (* P ⁇ 0.05, ** P ⁇ 0.005, *** P ⁇ 0.0005, NS: not significant vs. VEH).
  • Examples 1 to 4 which are a mixture of an indirubin derivative represented by Formula 1-2 and a metabolic activator, have a ratio of 75 to 95% or more than minoxidil (MNX), a conventional hair loss treatment agent. It showed an effect of increasing the length of vibrissa, and the length of vibrissa increased compared to Comparative Examples 1 to 9 (single-treatment) in which the indirubin derivative or metabolic activator represented by Formula 1-2 was administered alone. It was confirmed that was 20% to 40% or more.
  • MNX minoxidil
  • Comparative Examples 1 to 9 in which the indirubin derivative or metabolic activator represented by Formula 1-2 was administered alone, produced an increase effect of only about 1.25 times that of minoxidil (MNX), a conventional hair loss treatment, It can be seen that Examples 1 to 4 achieve significantly more significant effects than the simple synergistic effect of Comparative Examples 1 to 9.
  • the mixed composition prepared in Examples 1 to 4 of the present invention can be used as a composition useful for preventing hair loss and promoting hair growth.
  • Human dermal papilla cells were fixed at a rate of 2 ⁇ 10 5 per well of a 6-well plate, and when the cells were stably attached, they were treated with the drugs of Examples or Comparative Examples. . After 24 hours, luminescence values were measured using a FLUOstar OPTIMA luminometer (BMG Labtech, Offenburg, Germany) using the Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega, Madison, USA).
  • Figure 5 shows the cell viability of human dermal papilla cells treated with indirubin derivatives and metabolic activators (TEPP-46, DASA-58, Serine, UK-5099, Dichloroacetate) alone or in combination. This is the graph shown (* P ⁇ 0.05, ** P ⁇ 0.005, *** P ⁇ 0.0005 vs VEH).
  • the indirubin derivative represented by Formula 1-2 and the metabolic activator did not show cytotoxicity either alone or in combination. That is, in Examples 1 to 4 and Comparative Examples 1 to 12, it was confirmed that the cell viability was more than 100%, confirming that the cell stability was very excellent. However, in the case of minoxidil (MNX), it was confirmed to be 97%, the only one below 100%.
  • C57BL/6N mice were used as experimental animals considering ease of experimentation.
  • the experimental animals used were 7-week-old male C57BL/6N normal mice weighing approximately 25g purchased from Orient Bio Co., Ltd. Five animals were assigned to each experimental group.
  • all hair follicles enter the anagen phase of the hair growth cycle from birth and begin to grow hair. After about 3 weeks, the mouse transitions to the telogen phase and immediately enters the second growth phase. It is known that all hair follicles transition into the telogen phase around 6-7 weeks, so this telogen phase is appropriate for evaluating the efficacy of only the experimental substance since the influence of the test animal's own hair growth factors is excluded.
  • the hair on the back of a 7-week-old C57BL/6N mouse was removed using an animal clipper.
  • the experiment was conducted by dividing the animals into 5 groups with 5 animals per group. Except for the normal group, 150 ⁇ l of the drug was applied to the back skin once a day for 28 days. Drugs were administered, and 4 weeks later, they were euthanized using carbon dioxide and photographs were taken. To compare the degree of hair growth, hair growth during the anagen phase was observed after 4 weeks by measuring the weight of the regrown hair. Among all areas of hair loss, the weight of the area where hair grew during the anagen phase was measured.
  • VHE Normal group
  • TEPP46 First comparison group
  • Second comparison group (KY19382): 150 ⁇ l of KY19382 (0.5 mM) was applied to the back skin once a day for 28 days.
  • MNX Third comparison group
  • Figure 6 is a photograph taken of each group treated with indirubin derivative and metabolic activator (TEPP-46) alone or in combination
  • Figure 7 is a photograph of each group treated with indirubin derivative and metabolic activator (TEPP-46) alone or in combination. This is a graph showing the hair growth values measured from each treated group (* P ⁇ 0.05, ** P ⁇ 0.005, *** P ⁇ 0.0005, NS: not significant vs VEH or single treat).
  • the composition combining the indirubin derivative (KY19382) and the metabolic activator (TEPP-46) of the present invention was compared and reviewed for hair loss improvement effect with MNX, an existing hair loss improvement agent, and as a result, the indirubin derivative (KY19382) and the metabolic activator were compared. It was confirmed that the composition mixed with the agent (TEPP-46) promoted hair growth during the growth period and showed significantly significant hair growth efficacy. In addition, the mixed composition of indirubin derivative (KY19382) and metabolic activator (TEPP-46) did not show inflammation or other pathological findings and was confirmed to be stable in cytotoxicity tests. Based on this, it was confirmed as an improvement or treatment for hair loss. You can see that it is available.
  • Formulation Example 1 Cream-type cosmetic composition for preventing or improving hair loss
  • composition of Example 1 an attempt was made to prepare a cream-type cosmetic composition for preventing or improving hair loss containing a mixed composition of an indirubin derivative of Formula 1-2 and a metabolic activator (TEPP-46) as an active ingredient.
  • Components including the composition of Example 1 were mixed according to the following amounts to prepare a cream-type cosmetic composition for preventing or improving hair loss.
  • Formulation Example 2 Pharmaceutical composition (ointment) for preventing or treating hair loss
  • composition for preventing or treating hair loss containing a mixed composition of an indirubin derivative of Formula 1-2 and a metabolic activator (TEPP-46) as an active ingredient.
  • Components including the composition of Example 1 were mixed according to the following amounts to prepare a pharmaceutical composition (ointment) for preventing or treating hair loss.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux, comprenant un dérivé d'indirubine et un activateur métabolique. La composition, selon la présente invention, peut être efficacement utilisée en tant que composition pharmaceutique ou composition cosmétique qui peut prévenir la chute des cheveux ou favoriser la pousse des cheveux, et peut être utilisée dans des produits cosmétiques fonctionnels ayant des propriétés de promotion de la pousse des cheveux ou de prévention de la chute des cheveux présentées à partir d'une fonction de prévention de la chute des cheveux, comprenant un promoteur de la pousse des cheveux.
PCT/KR2023/004211 2022-03-29 2023-03-29 Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un dérivé d'indirubine et un activateur métabolique WO2023191515A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2022-0039048 2022-03-29
KR20220039048 2022-03-29
KR1020230015930A KR20230141447A (ko) 2022-03-29 2023-02-07 인디루빈 유도체 및 대사활성화제를 포함하는 탈모 방지 또는 발모 촉진용 조성물
KR10-2023-0015930 2023-02-07

Publications (1)

Publication Number Publication Date
WO2023191515A1 true WO2023191515A1 (fr) 2023-10-05

Family

ID=88203120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/004211 WO2023191515A1 (fr) 2022-03-29 2023-03-29 Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un dérivé d'indirubine et un activateur métabolique

Country Status (1)

Country Link
WO (1) WO2023191515A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130103148A (ko) * 2012-03-09 2013-09-23 연세대학교 산학협력단 메틸 바닐레이트를 유효성분으로 함유하는 골 질환 예방 및 치료용 약학조성물
US20180186885A1 (en) * 2015-06-16 2018-07-05 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
KR20190013575A (ko) * 2017-08-01 2019-02-11 주식회사 씨케이바이오텍 탈모 방지 또는 발모 촉진용 조성물
US20200157093A1 (en) * 2017-06-30 2020-05-21 The Regents Of The University Of California Compositions and methods for modulating hair growth
KR20210003799A (ko) * 2018-04-13 2021-01-12 노쓰 캐롤라이나 스테이트 유니버시티 모발 성장 촉진을 위한 마이크로니들 패치의 사용

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130103148A (ko) * 2012-03-09 2013-09-23 연세대학교 산학협력단 메틸 바닐레이트를 유효성분으로 함유하는 골 질환 예방 및 치료용 약학조성물
US20180186885A1 (en) * 2015-06-16 2018-07-05 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
US20200157093A1 (en) * 2017-06-30 2020-05-21 The Regents Of The University Of California Compositions and methods for modulating hair growth
KR20190013575A (ko) * 2017-08-01 2019-02-11 주식회사 씨케이바이오텍 탈모 방지 또는 발모 촉진용 조성물
KR20210003799A (ko) * 2018-04-13 2021-01-12 노쓰 캐롤라이나 스테이트 유니버시티 모발 성장 촉진을 위한 마이크로니들 패치의 사용

Similar Documents

Publication Publication Date Title
WO2020122360A1 (fr) Procédé de préparation d'un extrait de zizania latifolia turcz. traité avec une enzyme présentant une teneur accrue en tricine, et composition de blanchissement, réduction des rides, anti-inflammatoire, antiallergique et d'hydratation, préparée avec ce dernier
WO2016159567A2 (fr) Composition pour favoriser la croissance capillaire ou la régénération capillaire, et à effet anti-inflammatoire
WO2014163219A1 (fr) Nouveau dérivé de phytospingosine-1-phosphate, procédé de préparation de celui-ci, et composition pour prévenir et traiter la perte des cheveux ou pour stimuler la croissance des cheveux comprenant celui-ci
WO2015037891A1 (fr) Agent de blanchiment de la peau contenant un nouveau composé cyclique
WO2010123184A1 (fr) Composition pour prévenir et traiter l'alopécie, à base de composés de norgalanthamine
WO2024049120A1 (fr) Composition cosmétique contenant un extrait extrait au moyen d'un solvant eutectique naturel respectueux de l'environnement
WO2019093608A1 (fr) Composition pharmaceutique ou cosmétique pour prévenir ou traiter la chute des cheveux ou favoriser la pousse des cheveux
WO2020218720A1 (fr) Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine
WO2014003232A1 (fr) Composition comprenant un extrait de dendropanax morbifera léveille en tant que principe actif pour la favorisation de la pousse des cheveux
WO2018062820A1 (fr) Composition visant à prévenir la chute des cheveux et à en favoriser la pousse, comprenant un phytoœstrogène en tant que principe actif
WO2023191515A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un dérivé d'indirubine et un activateur métabolique
WO2010027221A2 (fr) Composition de blanchiment de la peau contenant un extrait, une fraction ou un compose issu de lindera erythrocarpa
WO2020085826A1 (fr) Composition pour soulager une irritation de la peau induite par des facteurs de pollution environnementaux ou pour la protection de la peau, contenant comme principe actif un extrait de noix de muscade ou du macelignane
WO2019027239A2 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux
WO2020032435A1 (fr) Composition de prévention de la perte des cheveux ou de promotion de la restauration capillaire contenant du yarayara en tant qu'ingrédient actif
WO2015037855A1 (fr) Composition comprenant un extrait d'herbes combinées comprenant de l'acanthopanax koreanum naka et du crinum asiaticum var. japonicum présentant une activité de prévention de la calvitie et une activité de stimulation de la croissance capillaire
WO2023277584A1 (fr) Composition pour éliminer les cellules sénescentes comprenant un composé sélénié en tant que principe actif
WO2021230677A1 (fr) Nouveau composé polyphénol et composition antifongique contenant celui-ci en tant que principe actif
WO2017142368A2 (fr) Composition permettant de prévenir et de traiter une maladie cutanée allergique ou inflammatoire
WO2013024960A1 (fr) Composition médicale contenant un extrait de stauntonia hexaphylla
WO2015005700A1 (fr) Composition permettant de favoriser la repousse des cheveux et la croissance des cheveux
WO2019083286A2 (fr) Composition contenant de l'irone comme principe actif pour prévenir la chute des cheveux ou stimuler la repousse des cheveux
WO2023146274A1 (fr) Composition permettant de prévenir, de soulager ou de traiter l'alopécie ou la poliose par la régulation de l'aldéhyde déshydrogénase 2
WO2019083287A2 (fr) Composition contenant du phellandrène comme principe actif pour prévenir la chute des cheveux ou stimuler la repousse des cheveux
WO2022231294A1 (fr) Composition destinée à prévenir, à atténuer ou à traiter la pigmentation de la peau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23781368

Country of ref document: EP

Kind code of ref document: A1